169 related articles for article (PubMed ID: 15702857)
21. Pattern of drug resistant Helicobacter pylori in dyspeptic patients in Thailand.
Tangmankongworakoon N; Mahachai V; Thong-Ngam D; Vilaichone RK; Tumwasorn S; Kullavanijaya P
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S439-44. PubMed ID: 12930022
[TBL] [Abstract][Full Text] [Related]
22. Clarithromycin resistance and eradication of Helicobacter pylori in children.
Kalach N; Benhamou PH; Campeotto F; Bergeret M; Dupont C; Raymond J
Antimicrob Agents Chemother; 2001 Jul; 45(7):2134-5. PubMed ID: 11408237
[TBL] [Abstract][Full Text] [Related]
23. [The prevalence and mechanism of Helicobacter pylori resistance to clarithromycin in Beijing].
Zheng X; Hu F; Wang W
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(23):1413-5. PubMed ID: 11930609
[TBL] [Abstract][Full Text] [Related]
24. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Moayyedi P; Ragunathan PL; Mapstone N; Axon AT; Tompkins DS
J Gastroenterol; 1998 Apr; 33(2):160-3. PubMed ID: 9605943
[TBL] [Abstract][Full Text] [Related]
25. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.
Benson CA; Williams PL; Cohn DL; Becker S; Hojczyk P; Nevin T; Korvick JA; Heifets L; Child CC; Lederman MM; Reichman RC; Powderly WG; Notario GF; Wynne BA; Hafner R
J Infect Dis; 2000 Apr; 181(4):1289-97. PubMed ID: 10762562
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Helicobacter pylori strainsisolated before and after therapy.
Andrzejewska E; Szkaradkiewicz A; Klincewicz H; Linke K
Med Sci Monit; 2003 Sep; 9(9):CR400-4. PubMed ID: 12960930
[TBL] [Abstract][Full Text] [Related]
27. Antibiotic susceptibilities of Helicobacter pylori.
Bindayna KM
Saudi Med J; 2001 Jan; 22(1):53-7. PubMed ID: 11255612
[TBL] [Abstract][Full Text] [Related]
28. [Antibiotic resistance among strains of Helicobacter pylori in Gothenburg. Bacteria resistant to metronidazole].
Jaup BH; Brandberg A; Stenquist B; Norrby A
Lakartidningen; 1998 Jan; 95(4):279-81. PubMed ID: 9469961
[TBL] [Abstract][Full Text] [Related]
29. [Antimicrobial resistant test of H. pylori].
Inoue K; Satoh K; Muto H; Sugano K
Nihon Rinsho; 2001 Feb; 59(2):291-5. PubMed ID: 11218400
[TBL] [Abstract][Full Text] [Related]
30. [Resistance of Helicobacter pylori to clarithomycin].
Petersen AM; Schradieck W; Krogfelt KA
Ugeskr Laeger; 1998 Jun; 160(23):3412-3. PubMed ID: 9627511
[TBL] [Abstract][Full Text] [Related]
31. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.
Gut; 1997 Jul; 41(1):8-13. PubMed ID: 9274464
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility of Helicobacter pylori to metronidazole.
Perna F; Gatta L; Figura N; Ricci C; Tampieri A; Holton J; Miglioli M; Vaira D
Am J Gastroenterol; 2003 Oct; 98(10):2157-61. PubMed ID: 14572561
[TBL] [Abstract][Full Text] [Related]
33. Resistance of Helicobacter pylori to macrolides and nitroimidazole compounds. The current situation.
Mégraud F; Occhialini A; Doermann HP
J Physiol Pharmacol; 1997 Sep; 48 Suppl 4():25-38. PubMed ID: 9440053
[TBL] [Abstract][Full Text] [Related]
34. [Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid].
Toro C; García-Samaniego J; Carbó J; Iñiguez A; Alarcón T; López-Brea M; Baquero M
Rev Esp Quimioter; 2001 Jun; 14(2):172-6. PubMed ID: 11704771
[TBL] [Abstract][Full Text] [Related]
35. Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy.
Enroth H; Björkholm B; Engstrand L
Clin Infect Dis; 1999 Jun; 28(6):1305-7. PubMed ID: 10451171
[TBL] [Abstract][Full Text] [Related]
36. [Characteristics of anti-microbial agents and its clinical choice for H. pylori treatment].
Aoyama N; Shirasaka D; Sakai T; Shirakawa K
Nihon Rinsho; 1999 Jan; 57(1):43-52. PubMed ID: 10036934
[TBL] [Abstract][Full Text] [Related]
37. The incidence of non ulcer dyspepsia and its response to treatment.
Khan J; Javed M
J Ayub Med Coll Abbottabad; 2001; 13(4):30-1. PubMed ID: 11873428
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the triple therapy: proton pomp inhibitors, amoxicillin and tynidazole in Helicobacter pylori infection treatment.
Kos M; Zinkiewicz K; Stefanek J; Dabrowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):161-6. PubMed ID: 12898919
[TBL] [Abstract][Full Text] [Related]
39. Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia.
Parasakthi N; Goh KL
Am J Gastroenterol; 1995 Mar; 90(3):519. PubMed ID: 7872306
[No Abstract] [Full Text] [Related]
40. In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin.
Pilotto A; Franceschi M; Rassu M; Furlan F; Scagnelli M
Am J Gastroenterol; 2000 Mar; 95(3):833-4. PubMed ID: 10710100
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
